// App-Quantinova.ai

SAT0131 : CARDIO- AND CEREBROVASCULAR RISK WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS) IN RHEUMATOID ARTHRITIS (RA): A REAL-WORLD COMPARATIVE ASSESSMENT

Researchers

Presenter

  • A. Prats-Uribe

Principal Investigators

  • B. Illingens

  • D. Vizcaya

  • J. Weaver

  • E. Burn

  • R. Sawant

  • K. Marinier

  • P. Ryan

  • D. Prieto-Alhambra

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Beth Israel Deaconess Medical Center, Department of Neurology, Harvard Medical School, Harvard, United States of America

  • Bayer Iberia, Barcelona, Spain

  • Janssen Research and Development, New Jersey, United Kingdom

  • Idiap Jordi Gol, UAB, Barcelona, Spain

  • Abbvie,Health Economics and Outcomes Research, North Chicago, United States of America

  • Servier, Suresnes, France

  • Janssen Research and Development, Titusville, New Jersey, United States of America

  • University of Oxford, Oxford, United Kingdom

Locations

  • United Kingdom

  • United States

  • Spain

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved